104960-56-7 Usage
General Description
3-AMINO-6-PHENYL-4-(TRIFLUOROMETHYL)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID is a chemical compound with potential pharmacological activity. It contains an amino group, a phenyl group, a trifluoromethyl group, and a thiophene ring fused with a pyridine ring, as well as a carboxylic acid functional group. 3-AMINO-6-PHENYL-4-(TRIFLUOROMETHYL)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID may have applications in medicinal chemistry and drug development, as it possesses structural features that are found in biologically active molecules. Furthermore, the presence of the carboxylic acid group suggests that it may be capable of forming various derivatives and analogs with potentially diverse biological activities. Therefore, further research on this compound and its derivatives may lead to the discovery of new drugs or therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 104960-56-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,9,6 and 0 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 104960-56:
(8*1)+(7*0)+(6*4)+(5*9)+(4*6)+(3*0)+(2*5)+(1*6)=117
117 % 10 = 7
So 104960-56-7 is a valid CAS Registry Number.
104960-56-7Relevant articles and documents
Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors
Wang, Ning-Yu,Zuo, Wei-Qiong,Xu, Ying,Gao, Chao,Zeng, Xiu-Xiu,Zhang, Li-Dan,You, Xin-Yu,Peng, Cui-Ting,Shen, Yang,Yang, Sheng-Yong,Wei, Yu-Quan,Yu, Luo-Ting
, p. 1581 - 1588 (2014/03/21)
Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[2,3-b]pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 μM, SI >30.3, 12b, EC50 = 3.5 μM, SI >28.6, 10l, EC50 = 3.9 μM, SI >25.6, 12o, EC 50 = 4.5 μM, SI >22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents.
Xi:Irritant;
